ECYT - Endocyte, Inc.

. Currency in USD
Stock chart is not supported by your current browser
Previous CloseN/A
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52 Week Rangeundefined - undefined
VolumeN/A
Avg. VolumeN/A
Market CapN/A
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Novartis CEO talks chasing cures over profitable treatments, says they will 'ultimately' be valued
    CNBC4 months ago

    Novartis CEO talks chasing cures over profitable treatments, says they will 'ultimately' be valued

    Jim Cramer and Novartis CEO Vas Narasimhan discuss how the drugmaker is refocusing its business to leverage new-age treatments and potential cures.

  • GlobeNewswire5 months ago

    Endocyte Stockholders Approve Merger Agreement with Novartis AG

    Endocyte, Inc. (ECYT) (“Endocyte”), a biopharmaceutical company developing targeted therapeutics for cancer treatment, today announced that at its Special Meeting of Stockholders held earlier today, Endocyte’s stockholders approved the adoption of the merger agreement pursuant to which Novartis AG will acquire Endocyte for $24 per share, or a total equity value of approximately $2.1 billion, in cash.

  • Why Arrowhead Pharmaceuticals Stock Rose Over 10% Yesterday
    Market Realist5 months ago

    Why Arrowhead Pharmaceuticals Stock Rose Over 10% Yesterday

    On December 12, Arrowhead Pharmaceuticals (ARWR) stock closed at $12.19, an ~11.53% rise from its previous day’s close of $13.62. Arrowhead Pharmaceuticals stock rose from $3.68 at the close of market on December 29, 2017, to reach $15.19 at the close of market on December 12, reflecting a ~313% year-to-date rise.

  • Do Hedge Funds Love Endocyte, Inc. (ECYT)?
    Insider Monkey5 months ago

    Do Hedge Funds Love Endocyte, Inc. (ECYT)?

    Legendary investors such as Leon Cooperman and Seth Klarman earn enormous amounts of money for themselves and their investors by doing in-depth research on small-cap stocks that big brokerage houses don’t publish. Small cap stocks -especially when they are screened well- can generate substantial outperformance versus a boring index fund. That’s why we analyze the […]

  • Endocyte Stock Has Seen a Solid Hike in 2018
    Market Realist6 months ago

    Endocyte Stock Has Seen a Solid Hike in 2018

    Endocyte (ECYT) stock rose from $4.28 at the close of market on December 29, 2017, to $23.60 at the close of market on November 20, 2018, representing ~451% YTD (year-to-date) growth. Endocyte hit its 52-week high of $23.89 on November 5. In October, Endocyte announced a merger with Novartis (NVS).

  • PR Newswire6 months ago

    Monteverde & Associates PC Files Class Action Lawsuit On Behalf Of Shareholders Of Endocyte, Inc. In The U.S. District Court For The Southern District Of New York

    NEW YORK, Nov. 16, 2018 /PRNewswire/ -- Notice is hereby given that Monteverde & Associates PC has filed a class action lawsuit in the United States District Court for the Southern District of New York, Case No. 1:18-cv-10392-JMF, on behalf of public common shareholders of Endocyte, Inc. ("Endocyte" or the "Company") (ECYT)  who held Endocyte securities on the record date November 15, 2018 (the "Class Period"), and have been harmed by Endocyte and its board of directors' (the "Board") alleged violations of Sections 14(a) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") in connection with the sale of the Company to affiliates of  Novartis AG ( the "Proposed Merger").

  • A Closer Look at Insys Therapeutics’ Performance Year-to-Date
    Market Realist6 months ago

    A Closer Look at Insys Therapeutics’ Performance Year-to-Date

    Insys Therapeutics (INSY) is among the specialty pharmaceutical companies that focus on developing cannabinoids and sprays.

  • GlobeNewswire6 months ago

    Recent Analysis Shows Audentes Therapeutics, Endocyte, Bluerock Residential Growth REIT, Air Products and Chemicals, BWX Technologies, and Modine Manufacturing Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, Nov. 09, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Endocyte (ECYT) Reports Q3 Loss, Tops Revenue Estimates
    Zacks6 months ago

    Endocyte (ECYT) Reports Q3 Loss, Tops Revenue Estimates

    Endocyte (ECYT) delivered earnings and revenue surprises of -6.25% and 330.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press6 months ago

    Endocyte: 3Q Earnings Snapshot

    On a per-share basis, the West Lafayette, Indiana-based company said it had a loss of 17 cents. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...

  • GlobeNewswire6 months ago

    Endocyte Provides Third Quarter 2018 Financial Results and Operational Update

    Endocyte, Inc. (ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced financial results for the third quarter ended Sept. 30, 2018 and provided an operational update. “177Lu-PSMA-617’s value as a potential treatment for patients with mCRPC has been reinforced in both our regulatory interactions and our entry into a merger agreement with Novartis AG, along with our longstanding interactions with patients and physicians in the prostate cancer community,” said Mike Sherman, president and CEO of Endocyte. Announced on October 18, 2018, our entry into an agreement and plan of merger with Novartis AG (Novartis), subject to the terms and conditions of which Novartis will acquire Endocyte for $24 per share, or a total equity value of approximately $2.1 billion, in cash.

  • Reuters7 months ago

    Bayer CEO backs group's diversified structure

    Bayer's (BAYGn.DE) chief executive reaffirmed his support for a corporate structure made up of healthcare, crop science and animal health businesses, after analysts called for a breakup to shore up its flagging share price. Shares in drugmaker Bayer, which bought Monsanto for $63 billion (£48.4 billion) , have lost more than 25 percent since a U.S. jury in August found its glyphosate-based weedkillers responsible for a man's terminal cancer, with more than 8,700 plaintiffs also seeking damages. "We have announced our strategy in September 2014, which has not changed to date," Chief Executive Werner Baumann told journalists in St. Louis at the former Monsanto headquarters where Bayer's seed business is now based.

  • PR Newswire7 months ago

    SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Endocyte, Inc. - ECYT

    NEW YORK , Nov. 1, 2018 /PRNewswire/ --  Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a boutique securities firm headquartered at the Empire State Building in New York ...

  • Zacks.com featured highlights include: Lamb Weston, Dollar General, Endocyte and CONSOL
    Zacks7 months ago

    Zacks.com featured highlights include: Lamb Weston, Dollar General, Endocyte and CONSOL

    Zacks.com featured highlights include: Lamb Weston, Dollar General, Endocyte and CONSOL

  • Can The Uptrend Continue for Endocyte (ECYT)?
    Zacks7 months ago

    Can The Uptrend Continue for Endocyte (ECYT)?

    Investors certainly have to be happy with Endocyte, Inc. (ECYT) and its short term performance.

  • Benzinga7 months ago

    The Daily Biotech Pulse: Novartis Positive Liver Drug Trials, Krytstal Prices Offering, LogicBio To Debut

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 18) Endocyte, Inc. (NASDAQ: ECYT )( announced a deal to ...

  • ACCESSWIRE7 months ago

    Today’s Research Reports on Stocks to Watch: Proteostasis Therapeutics and Endocyte

    NEW YORK, NY / ACCESSWIRE / October 19, 2018 / Shares of biotech stocks Proteostasis Therapeutics and Endocyte were seeing big gains on different exciting announcements. Proteostasis announced encouraging preliminary results while traders learned that Endocyte will be purchased by Novartis for $2.1 billion. Proteostasis Therapeutics, Inc. shares closed up 447.62% on Thursday on skyrocket volume of about 94 million shares.

  • Stocks plunge, Dow falls 327 points
    Yahoo Finance7 months ago

    Stocks plunge, Dow falls 327 points

    All three of the major indices sold off into the close on Thursday, and the selling accelerated midday after Treasury Secretary Steven Mnuchin announced that he will not be attending a summit in Saudi Arabia.

  • Novartis to Buy Biopharmaceutical Company Endocyte for $2.1 Billion
    GuruFocus.com7 months ago

    Novartis to Buy Biopharmaceutical Company Endocyte for $2.1 Billion

    Expanding further into the increasingly competitive field of oncology, Swiss drugmaker Novartis AG (NVS) announced on Thursday morning it is buying biopharmaceutical company Endocyte Inc. (ECYT) in a deal valued at $2.1 billion. Warning! GuruFocus has detected 3 Warning Signs with NVS. According to the terms of the all-cash agreement, Novartis will pay $24 per share for the West Lafayette, Indiana-based company, a 54% premium to the stock's closing price on Oct. 17.